Results 21 to 30 of about 3,663 (172)

Regional differences in physicians’ behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study

Frontiers in Cardiovascular Medicine, 2023
BackgroundDespite better accessibility of the effective lipid-lowering therapies, only about 20% of patients at very high cardiovascular risk achieve the low-density lipoprotein cholesterol (LDL-C) goals.
Maciej Banach, Maciej Banach, Maciej Banach, Maciej Banach, Joanna Lewek, Joanna Lewek, Kaja Pol, Daniel Rabczenko, Serban M. Balanescu, Vladimir Blaha, Richard Ceska, Piotr Jankowski, Piotr Jankowski, Stanisław Surma, Genovefa Kolovou, Evangelos Liberopoulos, Florin Mitu, Magda Mitu, Franjo Husam Naji, Gyorgy Paragh, Magdalena Popławska, Michal Vrablik, Daniel Pella   +22 more
doaj   +1 more source

Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin[S]

Journal of Lipid Research, 2014
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a potential novel strategy for treatment of CVD. Alirocumab is a fully human PCSK9 monoclonal antibody in phase 3 clinical development.
Susan Kühnast, José W.A. van der Hoorn, Elsbet J. Pieterman, Anita M. van den Hoek, William J. Sasiela, Viktoria Gusarova, Anusch Peyman, Hans-Ludwig Schäfer, Uwe Schwahn, J. Wouter Jukema, Hans M.G. Princen   +10 more
doaj   +1 more source

Early effects of PCSK9 inhibitors: evolocumab versus alirocumab [PDF]

Kosin Medical Journal
Background The significance of risk modification in patients with acute coronary syndrome (ACS) is well recognized; however, the optimal timing for adminstering PCSK9 inhibitors remains unclear. Additionally, the lipid-lowering efficacy of evolocumab and
Su-Hyun Bae, Bong-Joon Kim, Soo-Jin Kim, Sung-Il Im, Hyun-Su Kim, Jung-Ho Heo   +5 more
doaj   +1 more source

Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies

Cardiovascular Diabetology, 2019
Background Individuals with diabetes often have high levels of atherogenic lipoproteins and cholesterol reflected by elevated low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), and ...
Kausik K. Ray, Stefano Del Prato, Dirk Müller-Wieland, Bertrand Cariou, Helen M. Colhoun, Francisco J. Tinahones, Catherine Domenger, Alexia Letierce, Jonas Mandel, Rita Samuel, Maja Bujas-Bobanovic, Lawrence A. Leiter   +11 more
doaj   +1 more source

Effects of Alirocumab on Triglyceride Metabolism: A Fat-Tolerance Test and Nuclear Magnetic Resonance Spectroscopy Study

Biomedicines, 2022
Background: PCSK9 antibodies strongly reduce LDL cholesterol. The effects of PCSK9 antibodies on triglyceride metabolism are less pronounced. The present study aimed to investigate in detail the effects of alirocumab on triglycerides, triglyceride-rich ...
Thomas Metzner, Deborah R. Leitner, Karin Mellitzer, Andrea Beck, Harald Sourij, Tatjana Stojakovic, Gernot Reishofer, Winfried März, Ulf Landmesser, Hubert Scharnagl, Hermann Toplak, Günther Silbernagel   +11 more
doaj   +1 more source

Cost-Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after Myocardial Infarction in the Chinese Setting

Frontiers in Pharmacology, 2021
Background: Proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab reduce ischemic events; however, the cost-effectiveness remains uncertain.
Zhe Liang, Qi Chen, Ruiqi Wei, Chenyao Ma, Xuehui Zhang, Xue Chen, Fang Fang, Quanming Zhao   +7 more
doaj   +1 more source

Effect of Alirocumab on Coronary Calcification in Patients With Coronary Artery Disease

Frontiers in Cardiovascular Medicine, 2022
BackgroundProprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors have been documented with significantly reduction in LDL cholesterol levels and cardiovascular events.
Fei Gao, Yue Ping Li, Xiao Teng Ma, Zhi Jian Wang, Dong Mei Shi, Yu Jie Zhou   +5 more
doaj   +1 more source

A Retrospective Observational Study to Determine Baseline Characteristics and Early Prescribing Patterns for Patients Receiving Alirocumab in UK Clinical Practice

Drugs - Real World Outcomes, 2019
Background Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9) and has been previously shown, in the phase III ODYSSEY clinical trial program, to provide significant lowering of low-density lipoprotein
Tim Reynolds, Peter Carey, Jacob George, Gerasimos Konidaris, Deepa Narayanan, Sudarshan Ramachandran, Luke Saunders, Adie Viljoen, Gordon Ferns   +8 more
doaj   +1 more source

Efficacy and safety of PCSK9 inhibition in cardiovascular disease: a meta-analysis of 45 randomized controlled trials

Cardiology Journal, 2022
BACKGROUND: Safety concerns about proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors make physicians reluctant to prescribe agents for patients. The present aim was to assess the efficacy and safety of alirocumab, evolocumab and bococizumab
Qiang Geng, Xuan Li, Qingjiao Sun, Zhengzhong Wang   +3 more
doaj   +1 more source

Alirocumab for the treatment of hypercholesterolaemia

Expert Review of Clinical Pharmacology, 2017
Prescription of statins for low-density lipoprotein cholesterol (LDL-C) reduction is the standard of care in primary and secondary prevention of cardiovascular disease; nevertheless, a large number of patients treated with statins are unable to reach the recommended LDL-C targets.
DELLA PEPA, GIUSEPPE, BOZZETTO, LUTGARDA, ANNUZZI, GIOVANNI, RIVELLESE, ANGELA ALBAROSA   +3 more
openaire   +3 more sources